Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Jun 18, 2026 · Filed Jun 23, 2026
Vertex Pharmaceuticals's and CMO sold $471K of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$471,413
Shares × reported transaction price
45 days after results of May 4, 2026, 46 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $451.63 on Jun 18, 2026, 23% above its 52-week low and 10% below its high, after a 6% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $499.17 (Mar 10, 2026), 64% of the way up, from 251 adjusted closes. 30 trading days earlier: $427.65 on May 6, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.8% | +1.7% | +3.1% |
| 30 days | +0.5% | +0.8% | -0.3% |
| 90 days | +8.4% | +5.5% | +2.9% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
2 different filers disclosed VRTX within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.